

## Datasheet: MCA756SBV440

**BATCH NUMBER 64574797**

<b>Description:</b>	MOUSE ANTI HUMAN CD64:StarBright Violet 440
<b>Specificity:</b>	CD64
<b>Other names:</b>	FcRI
<b>Format:</b>	StarBright Violet 440
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	10.1
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	100 TESTS/0.5ml

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

### Target Species

Human

### Species Cross Reactivity

Reacts with: Baboon, Cynomolgus monkey, Rhesus Monkey  
**N.B.** Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.

### Product Form

Purified IgG conjugated to StarBright Violet 440 - liquid

Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	StarBright Violet 440	383	436

### Preparation

Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant

<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative</b>	0.09% Sodium Azide (NaN <sub>3</sub> )
<b>Stabilisers</b>	1% Bovine Serum Albumin 0.1% Pluronic F68 0.1% PEG 3350 0.05% Tween 20
<b>Immunogen</b>	Human monocytes
<b>External Database Links</b>	<p><b>UniProt:</b>  <a href="#">P12314</a>    <a href="#">Related reagents</a></p> <p><b>Entrez Gene:</b>  <a href="#">2209</a>    FCGR1A    <a href="#">Related reagents</a></p>
<b>Synonyms</b>	FCG1, FCGR1, IGFR1
<b>Fusion Partners</b>	Spleen cells from immunised BALB/c mice were fused with cells of the mouse SP2/0-Ag14 myeloma cell line
<b>Specificity</b>	<p><b>Mouse anti Human CD64 antibody, clone 10.1</b> recognizes the human CD64 cell surface antigen, a ~75 kDa glycoprotein expressed by monocytes. The antigen acts as a high affinity receptor for human IgG, and is also known as FcRI.</p> <p>Mouse anti Human CD64 antibody, clone 10.1 blocks binding of immunoglobulin to FcRI.</p>
<b>Flow Cytometry</b>	Use 5µl of the suggested working dilution to label 10 <sup>6</sup> cells in 100µl. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
<b>References</b>	<ol style="list-style-type: none"> <li>Scheinecker, C. <i>et al.</i> (1998) Initiation of the autologous mixed lymphocyte reaction requires the expression of costimulatory molecules B7-1 and B7-2 on human peripheral blood dendritic cells. <a href="#">J Immunol. 161: 3966-73.</a></li> <li>Fadlon, E. <i>et al.</i> (1998) Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. <a href="#">Blood. 91: 266-74.</a></li> <li>Navarro-López, F. <i>et al.</i> (2003) Late T-lymphocyte and monocyte activation in coronary restenosis. Evidence for a persistent inflammatory/immune mechanism? <a href="#">Rev Esp Cardiol. 56: 465-72.</a></li> <li>Beekman, J.M. <i>et al.</i> (2004) Direct interaction between FcγRI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity. <a href="#">Proc Natl Acad Sci U S A. 101: 10392-7.</a></li> <li>Kahn, F. <i>et al.</i> (2008) Antibodies against a surface protein of <i>Streptococcus pyogenes</i> promote a pathological inflammatory response. <a href="#">PLoS Pathog. 4 (9): e1000149.</a></li> <li>Wagner, C. <i>et al.</i> (2008) T lymphocytes in acute bacterial infection: increased prevalence of CD11b(+) cells in the peripheral blood and recruitment to the infected site.</li> </ol>

[Immunology. 125: 503-9.](#)

7. Eisenhardt, S.U. *et al.* (2009) Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. [Circ Res. 105: 128-37.](#)
8. Tanaka, M. *et al.* (2009) Activation of Fc gamma RI on monocytes triggers differentiation into immature dendritic cells that induce autoreactive T cell responses. [J Immunol. 183: 2349-55.](#)
9. Liu M *et al.* (2011) Vitellogenin mediates phagocytosis through interaction with FcγR. [Mol Immunol. 49 \(1-2\): 211-8.](#)
10. Fet, N.G. *et al.* (2012) Reduction of activated macrophages after ischaemia-reperfusion injury diminishes oxidative stress and ameliorates renal damage. [Nephrol Dial Transplant. 27 \(8\): 3149-55.](#)
11. Kapelski S *et al.* (2014) Assessment of the neutrophilic antibody-dependent respiratory burst (ADRB) response to *Plasmodium falciparum*. [J Leukoc Biol. 96 \(6\): 1131-42.](#)
12. Hristodorov, D. *et al.* (2016) Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages. [Immunol Cell Biol. 94 \(5\): 470-8.](#)
13. Loi, A.L.T. *et al.* (2017) Proteomic profiling of peripheral blood neutrophils identifies two inflammatory phenotypes in stable COPD patients. [Respir Res. 18 \(1\): 100.](#)
14. Rahabi, M. *et al.* (2020) Divergent Roles for Macrophage C-type Lectin Receptors, Dectin-1 and Mannose Receptors, in the Intestinal Inflammatory Response. [Cell Rep. 30 \(13\): 4386-98.e5.](#)
15. Tonecka, K. *et al.* (2021) The CD200 Regulates Inflammation in Mice Independently of TNF-α Production. [Int J Mol Sci. 22 \(10\): 5358.](#)

---

<b>Storage</b>	Store at +4°C. DO NOT FREEZE. This product should be stored undiluted.
<b>Guarantee</b>	12 months from date of despatch
<b>Acknowledgements</b>	This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #20471 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA756SBV440">https://www.bio-rad-antibodies.com/SDS/MCA756SBV440</a>
<b>Regulatory</b>	For research purposes only

---

## Related Products

### Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

**Product inquiries:** [www.bio-rad-antibodies.com/technical-support](http://www.bio-rad-antibodies.com/technical-support)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](http://bio-rad-antibodies.com/datasheets)

'M426511:240123'

Printed on 29 Jan 2026

